Infliximab in primary Sjögren's syndrome: One-year followup

Arthritis and Rheumatism

Volumn 46, Issue 12, 2002, Pages 3301-3303

  Steinfeld, Serge D ^a   Demols, Paul ^a   Appelboom, Thierry ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLIXIMAB;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEVER; FOLLOW UP; HUMAN; PILOT STUDY; PRIORITY JOURNAL; RASH; SJOEGREN SYNDROME; SYMPTOMATOLOGY; TONSILLITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FOLLOW-UP STUDIES; HUMANS; PILOT PROJECTS; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 0036899505     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10674     Document Type: Article

References (5)

1. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: A pilot study. Arthritis Rheum 2001;44:2371-5.
2. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome: Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36: 340-7.
3. Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjögren's syndrome: Proposed criteria for classification. Arthritis Rheum 1986;29:577-85.
4. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999;354:1932-9.
5. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor a monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.